201
Views
3
CrossRef citations to date
0
Altmetric
Short Report

The use of methotrexate in conservative treatment of placenta accreta spectrum disorders

ORCID Icon, , , &
Pages 7514-7517 | Received 16 Nov 2020, Accepted 30 Jun 2021, Published online: 18 Jul 2021
 

Abstract

Aim of the study: This article reports on a series of patients with placenta accreta spectrum (PAS) disorder who were treated conservatively with Methotrexate (MTX) administration with or without embolization. We investigate whether there is a place for MTX in conservative treatment of PAS.

Methods: We present a single-center retrospective case series of five patients. In all patients, diagnosis was unexpected and not made prenatally.

Conclusion: The benefits should be weighed against the possible drug toxicity. Today high-quality evidence is lacking. PAS covers a broad spectrum of pathology, standardization in prenatal and postnatal diagnosis can help to compare evidence on treatment.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access
  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart
* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.